{"id":"https://openalex.org/W2259308424","doi":"https://doi.org/10.1200/jco.2001.19.12.3130","title":"Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin","display_name":"Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin","alternate_titles":[],"publication_year":2001,"publication_date":"2001-06-15","ids":{"openalex":"https://openalex.org/W2259308424","doi":"https://doi.org/10.1200/jco.2001.19.12.3130","mag":"2259308424","pmid":"https://pubmed.ncbi.nlm.nih.gov/11408511"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2001.19.12.3130","doi":"https://doi.org/10.1200/jco.2001.19.12.3130","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2001.19.12.3130","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2259308424"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112536422","display_name":"Ronald Alan Peck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ronald A. Peck","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040993821","display_name":"Jan Hewett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jan Hewett","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030743286","display_name":"Matthew W. Harding","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Matthew W. Harding","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089911601","display_name":"Yow\u2010Ming Wang","orcid":"https://orcid.org/0000-0002-0663-7358","observed_orcids":["https://orcid.org/0000-0002-0663-7358"]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yow-Ming Wang","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111845671","display_name":"Pravin R. Chaturvedi","orcid":"https://orcid.org/0009-0006-3830-6293","observed_orcids":["https://orcid.org/0009-0006-3830-6293"]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pravin R. Chaturvedi","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025126436","display_name":"Anish Bhatnagar","orcid":"https://orcid.org/0000-0001-7078-6959","observed_orcids":["https://orcid.org/0000-0001-7078-6959"]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anish Bhatnagar","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080360970","display_name":"Harvey A. Ziessman","orcid":"https://orcid.org/0000-0001-9280-6914","observed_orcids":["https://orcid.org/0000-0001-9280-6914"]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Harvey Ziessman","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112041705","display_name":"Frank Atkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Frank Atkins","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103887854","display_name":"Michael Hawkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184565670","display_name":"Georgetown University","ror":"https://ror.org/05vzafd60","country_code":"US","type":"education","lineage":["https://openalex.org/I184565670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael J. Hawkins","raw_affiliation_strings":["From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Vincent T. Lombardi Cancer Research Center and Department of Nuclear Medicine, Georgetown University, Washington, DC, and Vertex Pharmaceuticals Incorporated, Cambridge, MA","institution_ids":["https://openalex.org/I184565670"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I184565670"],"apc_list":null,"apc_paid":null,"fwci":5.6288,"has_fulltext":false,"cited_by_count":111,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.96307495,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"19","issue":"12","first_page":"3130","last_page":"3141"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/p-glycoprotein-inhibitors","display_name":"P-glycoprotein inhibitors","score":0.8059999942779541},{"id":"https://openalex.org/keywords/multidrug-resistance-reversal","display_name":"multidrug resistance reversal","score":0.8190000057220459},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9470000267028809},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7490000128746033},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8360000252723694},{"id":"https://openalex.org/keywords/99mtc-sestamibi","display_name":"99mTc-sestamibi","score":0.8360000252723694},{"id":"https://openalex.org/keywords/hepatic-uptake","display_name":"hepatic uptake","score":0.699999988079071},{"id":"https://openalex.org/keywords/refractory-solid-tumors","display_name":"refractory solid tumors","score":0.7319999933242798},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.4690000116825104},{"id":"https://openalex.org/keywords/central-nervous-system-toxicity","display_name":"central nervous system toxicity","score":0.4350000023841858},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.9769999980926514},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.3720000088214874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8521440625190735},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7886440753936768},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7114498615264893},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.5998514294624329},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5627956390380859},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.5616374611854553},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4998290538787842},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4765506386756897},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.47357019782066345},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4213676452636719},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40130120515823364},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37096524238586426}],"mesh":[{"descriptor_ui":"D000074081","descriptor_name":"MutS Homolog 3 Protein","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004268","descriptor_name":"DNA-Binding Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008099","descriptor_name":"Liver","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D008099","descriptor_name":"Liver","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D011877","descriptor_name":"Radionuclide Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017256","descriptor_name":"Technetium Tc 99m Sestamibi","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020168","descriptor_name":"ATP Binding Cassette Transporter, Subfamily B, Member 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D027425","descriptor_name":"ATP-Binding Cassette, Sub-Family C Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2001.19.12.3130","doi":"https://doi.org/10.1200/jco.2001.19.12.3130","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2001.19.12.3130","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:11408511","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11408511","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":58,"referenced_works":["https://openalex.org/W42293926","https://openalex.org/W87795511","https://openalex.org/W206710202","https://openalex.org/W1537949979","https://openalex.org/W1545285984","https://openalex.org/W1780912673","https://openalex.org/W1829124730","https://openalex.org/W1866647776","https://openalex.org/W1900236741","https://openalex.org/W1925223276","https://openalex.org/W1947582981","https://openalex.org/W1949997781","https://openalex.org/W1953019510","https://openalex.org/W1964444964","https://openalex.org/W1972501728","https://openalex.org/W1973522717","https://openalex.org/W1974338599","https://openalex.org/W1980319850","https://openalex.org/W1986222466","https://openalex.org/W1988234658","https://openalex.org/W1993176598","https://openalex.org/W2002936028","https://openalex.org/W2004804291","https://openalex.org/W2005625670","https://openalex.org/W2011839805","https://openalex.org/W2012841076","https://openalex.org/W2034006687","https://openalex.org/W2044889252","https://openalex.org/W2049664564","https://openalex.org/W2051002936","https://openalex.org/W2056326337","https://openalex.org/W2056631099","https://openalex.org/W2063647772","https://openalex.org/W2070005495","https://openalex.org/W2077140502","https://openalex.org/W2082592174","https://openalex.org/W2084600496","https://openalex.org/W2087545397","https://openalex.org/W2099212515","https://openalex.org/W2102286060","https://openalex.org/W2108526067","https://openalex.org/W2109881154","https://openalex.org/W2121528021","https://openalex.org/W2142760505","https://openalex.org/W2145552401","https://openalex.org/W2150541366","https://openalex.org/W2156213555","https://openalex.org/W2168375838","https://openalex.org/W2184400890","https://openalex.org/W2210404574","https://openalex.org/W2255683021","https://openalex.org/W2264883746","https://openalex.org/W2277869106","https://openalex.org/W2321195922","https://openalex.org/W2326620573","https://openalex.org/W2333819954","https://openalex.org/W2414829702","https://openalex.org/W2416082800"],"related_works":["https://openalex.org/W1780912673","https://openalex.org/W2169120362","https://openalex.org/W7097466060","https://openalex.org/W2107013450","https://openalex.org/W2258215916","https://openalex.org/W2084600496","https://openalex.org/W1791352086","https://openalex.org/W2048424737","https://openalex.org/W4244435760","https://openalex.org/W1964444964"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"evaluate":[2],"the":[3,35,84,115,133],"safety,":[4],"tolerability,":[5],"and":[6,16,22,42,107,157,168,180,214,244],"pharmacokinetics":[7,201,245],"of":[8,13,32,38,64,79,87,110,172,207,216,225,246],"biricodar":[9],"(VX-710),":[10],"an":[11],"inhibitor":[12],"P-glycoprotein":[14],"(P-gp)":[15],"multidrug":[17],"resistance-associated":[18],"protein":[19],"(MRP1),":[20],"alone":[21,66],"with":[23,27,52,202,239],"doxorubicin":[24,89,231,249],"in":[25,132,174,196,218,237,253],"patients":[26,117,121,136,145,175,238],"advanced":[28],"malignancies.":[29,241],"The":[30,242],"effect":[31],"VX-710":[33,65,80,111,147,173,198,210,226,247],"on":[34,83],"tissue":[36],"distribution":[37],"(99m)Tc-sestamibi,":[39],"a":[40,61,73,76,203],"P-gp":[41,256],"MRP1":[43],"substrate,":[44],"was":[45,81,92,130],"also":[46],"evaluated.":[47],"PATIENTS":[48],"AND":[49],"METHODS:":[50],"Patients":[51],"solid":[53],"malignancies":[54,254],"refractory":[55,240],"to":[56,69,99,166,185,191],"standard":[57],"therapy":[58],"first":[59],"received":[60,138,177],"96-hour":[62,223],"infusion":[63,78,224],"at":[67,178,227],"20":[68],"160":[70,148,181],"mg/m(2)/h.":[71],"After":[72],"3-day":[74],"washout,":[75],"second":[77,85],"begun,":[82],"day":[86],"which":[88],"45":[90,232],"mg/m(2)":[91,233],"administered.":[93],"Cycles":[94],"were":[95,104,122,152,164,183],"repeated":[96],"every":[97],"21":[98],"28":[100,116],"days.":[101],"(99m)Tc-sestamibi":[102,217],"scans":[103],"performed":[105],"before":[106],"during":[108],"administration":[109],"alone.":[112],"RESULTS:":[113],"Of":[114],"who":[118,137,176],"enrolled,":[119],"25":[120],"eligible":[123],"for":[124],"analysis.":[125],"No":[126],"dose-limiting":[127],"toxicity":[128,156,236],"(DLT)":[129],"observed":[131],"nine":[134],"assessable":[135],"120":[139,179,228],"mg/m(2)/h":[140,182,229],"or":[141],"less.":[142],"Among":[143],"seven":[144],"receiving":[146],"mg/m(2)/h,":[149],"two":[150],"DLTs":[151],"seen:":[153],"reversible":[154],"CNS":[155],"febrile":[158],"neutropenia.":[159],"All":[160],"other":[161],"adverse":[162],"events":[163],"mild":[165],"moderate":[167],"reversible.":[169],"Plasma":[170],"concentrations":[171,189],"two-":[184],"fourfold":[186],"higher":[187],"than":[188],"required":[190],"fully":[192],"reverse":[193],"drug":[194],"resistance":[195],"vitro.":[197],"exhibited":[199],"linear":[200],"harmonic":[204],"mean":[205],"half-life":[206],"1.1":[208],"hours.":[209],"enhanced":[211],"hepatic":[212],"uptake":[213],"retention":[215],"all":[219],"patients.":[220],"CONCLUSION:":[221],"A":[222],"plus":[230,248],"has":[234],"acceptable":[235],"safety":[243],"warrant":[250],"efficacy":[251],"trials":[252],"expressing":[255],"and/or":[257],"MRP1.":[258]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2259308424","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
